Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma Corporation, a company focused on developing treatments for chronic hepatitis B, is set to announce its first quarter financial results for 2024 on May 2, alongside a corporate update. Interested parties can join the conference call and webcast on the same day, with the webcast being made available on Arbutus’s website after the event. The company is currently advancing its clinical pipeline, including the RNAi therapeutic imdusiran and the oral PD-L1 inhibitor AB-101, both of which are in early-stage clinical trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
